Lead Product(s): Pritelivir
Therapeutic Area: Infections and Infectious Diseases
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: AiCuris Anti-infective Cures
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 12, 2020
The companies are collaborating to develop an Early Access Program for pritelivir, for treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.